Abstract
In humans, glucocorticoid excess may cause neuropsychiatric symptoms, including psychosis and cognitive impairment, and glucocorticoid signaling hyperactivation may sensitize to substance of abuse. The aim of this work was to evaluate whether exposure to glucocorticoid excess triggers molecular changes in dopaminergic and opioidergic systems within relevant forebrain areas. We acutely exposed Sprague-Dawley rats to dexamethasone, a glucocorticoid analog, or vehicle and evaluated the mRNA expression of dopamine D1 and D2 receptors and enkephalin within the cortex, the striatum, and the midbrain.
Dexamethasone reduced mRNA expression of D1 receptor and enkephalin in the cortex. In the striatum, dexamethasone reduced the expression of D1 receptor mRNA, but not that of D2 receptor and enkephalin. No significant changes in D2 receptor mRNA expression were observed in the midbrain. Basal distribution of D1 and D2 receptor mRNA showed a clear-cut striatal/cortical gradient, while this distribution was less obvious for enkephalin mRNA. Dexamethasone increased the cortico-striatal separation in terms of D1 and D2 receptor mRNA expression.
These molecular changes may represent adaptive mechanisms to dexamethasone-induced potentiation of dopaminergic and opioidergic transmission, mostly in cortical areas.
Keywords: Cognition, cortex, cortisol, dexamethasone, gene expression, glucocorticoid, schizophrenia, striatum.
Current Molecular Pharmacology
Title:The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions
Volume: 6
Author(s): Felice Iasevoli, Luigi Aloj, Gianmarco Latte, Livia Avvisati, Federica Marmo, Carmine Tomasetti, Elisabetta F. Buonaguro, Chiara Simeoli, Rosario Pivonello, Annamaria Colao and Andrea de Bartolomeis
Affiliation:
Keywords: Cognition, cortex, cortisol, dexamethasone, gene expression, glucocorticoid, schizophrenia, striatum.
Abstract: In humans, glucocorticoid excess may cause neuropsychiatric symptoms, including psychosis and cognitive impairment, and glucocorticoid signaling hyperactivation may sensitize to substance of abuse. The aim of this work was to evaluate whether exposure to glucocorticoid excess triggers molecular changes in dopaminergic and opioidergic systems within relevant forebrain areas. We acutely exposed Sprague-Dawley rats to dexamethasone, a glucocorticoid analog, or vehicle and evaluated the mRNA expression of dopamine D1 and D2 receptors and enkephalin within the cortex, the striatum, and the midbrain.
Dexamethasone reduced mRNA expression of D1 receptor and enkephalin in the cortex. In the striatum, dexamethasone reduced the expression of D1 receptor mRNA, but not that of D2 receptor and enkephalin. No significant changes in D2 receptor mRNA expression were observed in the midbrain. Basal distribution of D1 and D2 receptor mRNA showed a clear-cut striatal/cortical gradient, while this distribution was less obvious for enkephalin mRNA. Dexamethasone increased the cortico-striatal separation in terms of D1 and D2 receptor mRNA expression.
These molecular changes may represent adaptive mechanisms to dexamethasone-induced potentiation of dopaminergic and opioidergic transmission, mostly in cortical areas.
Export Options
About this article
Cite this article as:
Iasevoli Felice, Aloj Luigi, Latte Gianmarco, Avvisati Livia, Marmo Federica, Tomasetti Carmine, Buonaguro F. Elisabetta, Simeoli Chiara, Pivonello Rosario, Colao Annamaria and Bartolomeis de Andrea, The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions, Current Molecular Pharmacology 2013; 6 (3) . https://dx.doi.org/10.2174/187446720603140415215941
DOI https://dx.doi.org/10.2174/187446720603140415215941 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
Call for Papers in Thematic Issues
Common mechanisms underpinning neurodevelopmental disorders and psychiatric diseases
A growing number of large-scale epidemiologic studies has strongly suggested that common mechanisms may be shared by aberrant brain development and psychiatric disorders. There is now an appreciation of synergic roles of genetic variants and environmental stress which profoundly affect the genome integrity and reshape brain development. This can lead ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Thin Metal Films in Resistivity-based Chemical Sensing
Current Analytical Chemistry Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Brain Serotonin, Psychoactive Drugs, and Effects on Reproduction
Central Nervous System Agents in Medicinal Chemistry Novel Mannich-bases as Potential Anticonvulsants: Syntheses, Characterization and Biological Evaluation
Central Nervous System Agents in Medicinal Chemistry Micro-/nano-electroporation for active gene delivery
Current Pharmaceutical Design Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes
Current Drug Targets Changes in E-Selectin Levels Predict Carotid Stenosis Progression after Carotid Artery Stenting
Current Neurovascular Research Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Stress and the Prodromal Phase of Psychosis
Current Pharmaceutical Design Some Wild-Growing Plant Species from Serbia and Montenegro as the Potential Sources of Drugs
Current Pharmaceutical Design Ventilatory Abnormalities During Exercise in Heart Failure: A Mini Review
Current Respiratory Medicine Reviews Flavonoids from Stem and Leaf of <i>Scutellaria Baicalensis</i> Georgi Inhibit the Phosphorylation on Multi-sites of Tau Protein Induced by Okadaic Acid and the Regulative Mechanism of Protein Kinases in Rats
Combinatorial Chemistry & High Throughput Screening On the Possible Relevance of Bottom-up Pathways in the Pathogenesis of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Formulation and Assessment of In Vivo Anti-Inflammatory Potential of Omega-3-Fatty Acid Loaded Self Emulsifying Nanoemulsion
Current Nanomedicine Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Current Medicinal Chemistry